Merck's odanacatib flies over Phase III hurdle
This article was originally published in Scrip
A Phase III trial of Merck & Co's novel investigational treatment for osteoporosis odanacatib has been closed early after a planned interim analysis showed better than expected efficacy, raising hopes that the product will prove a worthy successor to Merck's previous blockbuster bisphosphonate Fosamax (alendronate).
You may also be interested in...
Sanofi/Regeneron’s anti-PD-1 product Libtayo may be late to the NSCLC party but strong data from EMPOWER-Lung 1 suggest it could gain traction in the space, especially in patients with high PD-L1 expression levels.
Bausch seeks to add eyecare assets in Allegro deal. AstraZeneca hopes preclinical PCSK9 inhibitor from Dogma can compete with dyslipidemia leaders. Exelixis options ADC candidates from Catalent and NBE.
Two different outcomes for two different CD4/6 inhibitors – Eli Lilly’s Verzenio and Pfizer’s Ibrance – put the Lilly drug on track to be a new standard of care in high-risk early stage HR+, HER2-negative breast cancer. Novartis’s Kisqali could follow.